Dr. Reddy’s drug-free migraine management device now available in Europe

Dr. Reddy's Laboratories made waves in the digital therapeutics segment with the introduction of Nerivio® in Germany. Approved by the FDA, this drug-free wearable, non-invasive gadget has been CE-mark certified. It marks a significant step in the realm of migraine management. Utilizing Remote Electrical Neuromodulation (REN), Nerivio® offers acute and preventative therapy for migraines, catering to people aged 12 years and older.

Following its German debut, Nerivio® is set to launch in Spain and the UK, expanding its reach across Europe.

Migraine, a pervasive global health concern, affects millions worldwide, with around 8 to 10 million individuals in Germany alone. Dr. Reddy's embarks to manage this challenging issue, providing innovative solutions for pain management.

Initially launched in 2023 in India, this REN device has already made a momentous impact. Supported by the 'M-Free' patient support program, its users profit from a comprehensive suite of services tailored to enhance their journey towards migraine management. From personalized counselling and device demonstrations to doorstep delivery and flexible payment options, 'M-Free' ensures that patients receive the support they need to optimize their experience with this first-ever approved REN device in India.

Moreover, recognizing the importance of lifestyle modifications in migraine management, 'M-Free' goes beyond device assistance, offering additional resources such as nutritionist consultations, yoga, and meditation sessions. Emphasizing complete wellness, Dr. Reddy's restates its commitment to enabling individuals to a migraine-free path.